Chionh, Fiona
Gebski, Val
Al-Obaidi, Sheren J.
Mooi, Jennifer K.
Bruhn, Maressa A.
Lee, Chee K.
Chüeh, Anderly C.
Williams, David S.
Weickhardt, Andrew J.
Wilson, Kate
Scott, Andrew M.
Simes, John
Hardingham, Jennifer E.
Price, Timothy J.
Mariadason, John M. http://orcid.org/0000-0001-9123-7684
Tebbutt, Niall C. http://orcid.org/0000-0003-2613-5168
Funding for this research was provided by:
National Health and Medical Research Council (1017737, 1048088, 1048088)
Article History
Received: 2 July 2021
Accepted: 24 November 2021
First Online: 24 January 2022
Competing interests
: FC: honorarium—Roche. CKL: honoraria—Astra Zeneca, Novartis, Pfizer, Roche and Boehringer Ingelheim, advisory role—Astra Zeneca, Novartis, Pfizer and Boehringer Ingelheim, and travel/accommodation/other expenses from Astra Zeneca and Boehringer Ingelheim. AJW: honoraria—Merck, Bristol Myers Squibb, advisory role—Merck, Pfizer, Bristol Myers Squibb, Ipsen. The other authors declare no competing interests.